Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?

被引:36
|
作者
Barnard, Katharine D. [1 ]
Pinsker, Jordan E. [2 ]
Oliver, Nick [3 ]
Astle, Annabel [1 ]
Dassau, Eyal [2 ,4 ]
Kerr, David [2 ]
机构
[1] Univ Southampton, Human Dev & Hlth, Fac Med, Southampton SO16 6YD, Hants, England
[2] William Sansum Diabet Ctr, Santa Barbara, CA USA
[3] Univ London Imperial Coll Sci Technol & Med, London, England
[4] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA
基金
美国国家卫生研究院;
关键词
LOOP INSULIN DELIVERY; RANDOMIZED CROSSOVER; PARTICIPANTS; ADULTS;
D O I
10.1089/dia.2014.0316
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The primary focus of artificial pancreas (AP) research has been on technical achievements, such as time in range for glucose levels or prevention of hypoglycemia. Few studies have attempted to ascertain the expectations of users of AP technology. Subjects and Methods: Persons with type 1 diabetes and parents of children with type 1 diabetes were invited to take part in an online survey concerning future use and expectations of AP technology. The survey was advertised via Twitter, Facebook, and DiabetesMine, plus advocacy groups and charities including INPUT, Diabetes UK, and the Diabetes Research and Wellness Foundation. Quantitative responses were categorized on a 5-point Likert scale. Free text responses were analyzed using content analysis. Results: Two hundred sixty-six surveys were completed over a 1-month period. Two hundred forty participants indicated they were highly likely to use a fully automated 24-h AP. Approximately half of the respondents indicated they would be likely to use a device that only functioned overnight. Size, visibility, and lack of effectiveness were the top reasons for not wanting an AP. Despite perceived potential downsides, participants expressed a strong need for a device that will help minimize the burden of disease, help facilitate improved psychosocial functioning, and improve quality of life. Conclusions: The views of people who would use an AP are crucial in the development of such devices to ensure they are fit for use alongside biomedical and engineering excellence. Without this, it is unlikely that an AP will be sufficiently successful to meet the needs of users and to achieve their ultimate goals.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [31] The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands
    de Jongh, Dide
    Bunnik, Eline
    Ozcan, Behiye
    Zietse, Robert
    Massey, Emma
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2024, 38
  • [32] Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: A randomized crossover trial
    Gingras, V.
    Rabasa-Lhoret, R.
    Messier, V.
    Ladouceur, M.
    Legault, L.
    Haidar, A.
    DIABETES & METABOLISM, 2016, 42 (01) : 47 - 54
  • [33] An artificial Beta Cell for the Therapy of Type 1 Diabetes mellitus
    Pavlicek, V.
    DIABETOLOGE, 2015, 11 (08): : 655 - 656
  • [34] An artificial Beta Cell for the Therapy of Type 1 Diabetes mellitus
    Pavlicek, V.
    DIABETOLOGE, 2015, 11 (08): : 655 - 656
  • [35] Adding Heart Rate Signal to a Control-to-Range Artificial Pancreas System Improves the Protection Against Hypoglycemia During Exercise in Type 1 Diabetes
    Breton, Marc D.
    Brown, Sue A.
    Karvetski, Colleen Hughes
    Kollar, Laura
    Topchyan, Katarina A.
    Anderson, Stacey M.
    Kovatchev, Boris P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (08) : 506 - 511
  • [36] Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials
    Weisman, Alanna
    Bai, Johnny-Wei
    Cardinez, Marina
    Kramer, Caroline K.
    Perkins, Bruce A.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) : 501 - 512
  • [37] Pancreas volume and fat fraction in children with Type 1 diabetes
    Regnell, S. E.
    Peterson, P.
    Trinh, L.
    Broberg, P.
    Leander, P.
    Lernmark, A.
    Mansson, S.
    Larsson, H. Elding
    DIABETIC MEDICINE, 2016, 33 (10) : 1374 - 1379
  • [38] Artificial Pancreas Using a Personalized Rule-Based Controller Achieves Overnight Normoglycemia in Patients with Type 1 Diabetes
    Capel, Ismael
    Rigla, Mercedes
    Garcia-Saez, Gema
    Rodriguez-Herrero, Agustin
    Pons, Belen
    Subias, David
    Garcia-Garcia, Fernando
    Gallach, Maria
    Aguilar, Montserrat
    Perez-Gandia, Carmen
    Gomez, Enrique J.
    Caixas, Assumpta
    Elena Hernando, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (03) : 172 - 179
  • [39] Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Dai, Xia
    Luo, Zu-chun
    Zhai, Lu
    Zhao, Wen-piao
    Huang, Feng
    DIABETES THERAPY, 2018, 9 (03) : 1269 - 1277
  • [40] Evaluating the Experience of Children With Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over Multiple Days in a Diabetes Camp Setting
    Troncone, Alda
    Bonfanti, Riccardo
    Iafusco, Dario
    Rabbone, Ivana
    Sabbion, Alberto
    Schiaffini, Riccardo
    Galderisi, Alfonso
    Marigliano, Marco
    Rapini, Novella
    Rigamonti, Andrea
    Tinti, Davide
    Vallone, Valeria
    Zanfardino, Angela
    Boscari, Federico
    Del Favero, Simone
    Galasso, Silvia
    Lanzola, Giordano
    Messori, Mirko
    Di Palma, Federico
    Visentin, Roberto
    Calore, Roberta
    Leal, Yenny
    Magni, Lalo
    Losiouk, Eleonora
    Chernavvsky, Daniel
    Quaglini, Silvana
    Cobelli, Claudio
    Bruttomesso, Daniela
    DIABETES CARE, 2016, 39 (12) : 2158 - 2164